Lucid Diagnostics: Strong Buy Rating With Significant Market Potential Despite Near-Term Losses
TipRanksApr 15 05:15 ET
Express News | Lucid Diagnostics Inc : Ascendiant Capital Markets Cuts Target Price to $8 From $8.5
Moomoo 24/7Apr 14 23:06 ET
Buy Rating Affirmed for Lucid Diagnostics Amidst Strong EsoGuard Testing Growth and Clear Reimbursement Path
TipRanksApr 11 16:45 ET
Analysts Are Bullish on Top Healthcare Stocks: Lucid Diagnostics (LUCD), Werewolf Therapeutics (HOWL)
TipRanksApr 10 13:50 ET
Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and...
PR NewswireApr 8 08:30 ET
Buy Rating Affirmed for PAVmed With Strategic Focus on Lucid Diagnostics and Veris Cancer Care Amid Adjusted Price Target
TipRanksMar 29 07:46 ET
PAVmed Inc. (NASDAQ:PAVM) Q4 2023 Earnings Call Transcript
Yahoo FinanceMar 28 09:47 ET
Buy Rating for Lucid Diagnostics: Solid Test Volumes and Strategic Growth Initiatives Propel Market Position
TipRanksMar 28 07:07 ET
Buy Rating Affirmed for Lucid Diagnostics Amid Strong Financials and Strategic Growth Initiatives
TipRanksMar 27 14:45 ET
Lucid Diagnostics Is Maintained at Overweight by Cantor Fitzgerald
Lucid Diagnostics Is Maintained at Overweight by Cantor Fitzgerald
Dow JonesMar 27 10:13 ET
Express News | Cantor Fitzgerald Maintains Overweight on Lucid Diagnostics, Lowers Price Target to $3
Moomoo 24/7Mar 27 10:05 ET
Lucid Diagnostics Price Target Maintained With a $2.50/Share by Needham
Lucid Diagnostics Price Target Maintained With a $2.50/Share by Needham
Dow JonesMar 27 05:30 ET
Buy Rating Affirmed for Lucid Diagnostics Amidst Growing Test Volume and Strategic Positioning for Medicare Reimbursement
TipRanksMar 27 05:25 ET
Needham Reiterates Buy on Lucid Diagnostics, Maintains $2.5 Price Target
Needham analyst Mike Matson reiterates Lucid Diagnostics with a Buy and maintains $2.5 price target.
Analyst UpgradesMar 27 05:20 ET
Lucid Diagnostics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/27/2024 142.72% Needham → $2.5 Reiterates Buy → Buy 11/14/2023 142.72% Needham $2.8 → $2.5 Maintains Bu
BenzingaMar 27 05:18 ET
PAVmed 4Q Loss/Shr $1.98 >PAVM
PAVmed 4Q Loss/Shr $1.98 >PAVM
Dow JonesMar 26 19:33 ET
Press Release: PAVmed Provides Business Update and Fourth Quarter and Full Year 2023 Financial Results
PAVmed Provides Business Update and Fourth Quarter and Full Year 2023 Financial Results PR Newswire NEW YORK, March 26, 2024 Lucid's quarterly revenue increased 33 percent sequentially Launched wh
Dow JonesMar 26 19:32 ET
Earnings Call Summary | Lucid Diagnostics(LUCD.US) Q4 2023 Earnings Conference
The following is a summary of the Lucid Diagnostics Inc. (LUCD) Q4 2023 Earnings Call Transcript:Financial Performance:Lucid Diagnostics posted Q4 revenues of $1 million, marking a 33% increase from Q
moomoo AIMar 26 16:40 ET · Conference Call
Lucid Diagnostics Reports Preliminary Q4 Results
Seeking AlphaMar 25 17:55 ET
Lucid Diagnostics Q4 EPS $(0.23) Beats $(0.26) Estimate, Sales $1.04M Miss $1.05M Estimate
Lucid Diagnostics (NASDAQ:LUCD) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.26) by 11.54 percent. This is a 53.33 percent decrease over losses of $(
BenzingaMar 25 17:43 ET
No Data
No Data